Join the Fidabio Mobilization

Fachhochschule, Basel, implemented a Fida 1 instrument amongst others to carry out complex oligomeric analysis and develop comprehensive assays for determining molecular integrity.

The Jørgen Kjems Group at the Interdisciplinary Nanoscience Center at Aarhus University has after intensive testing implemented their first Fida 1 instrument primarily for protein-nucleotide interactions analysis.


Fachhochschule, Basel, got their second Fida 1 instrument.

DTU Bioengineering, Andreas H. Laustsen, has acquired a Fidabio system for high-throughput biophysical characterization of therapeutic antibodies etc.

Agilent has acquired a Fida 1 amongst others to enable them to ensure consistent, high quality of their antibodies through the determination of quantity and affinity with a single FIDA analysis.

Exosome therapeutics leader, Codiak Biosciences, Inc., has acquired a Fida 1 to quantify and characterise exosomes directly in the fermentation media.


A completely new way to quantify and characterize complex biology

Essential New insight

Quantitative data on complex protein binding, concentration, size etc.

Unmatched Accuracy

Speed up your decisions with fast development of specific assays.

A New Paradigm

Intuitive technology with high data reproducibility and built-in quality control.

The FIDA technology represents a revolution in the analysis of proteins and nanoparticles.

Join the new paradigm.

Brian Sørensen, CEO, LL.M., Fidabio.

At Fidabio, we are committed to assist you in accelerating your R&D projects. For this we have developed the FIDA technology enabling simple, accurate, and fast detection and characterization of proteins & nanoparticles under native conditions.